Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicines set out in the Schedule hereto:
Schedule
Product: | Lenalidomide Te Arai |
Active Ingredient: | Lenalidomide 5mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Te Arai BioFarma Limited |
Manufacturer: | Lotus Pharmaceutical Co Limited, Nantou City, Taiwan |
Note: This consent is given subject to the following conditions:
|
|
Note: This renewed consent is valid for two years from 24 October 2023. | |
Product: | Lenalidomide Te Arai |
Active Ingredient: | Lenalidomide 10mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Te Arai BioFarma Limited |
Manufacturer: | Lotus Pharmaceutical Co Limited, Nantou City, Taiwan |
Note: This consent is given subject to the following conditions:
|
|
Note: This renewed consent is valid for two years from 24 October 2023. | |
Product: | Lenalidomide Te Arai |
Active Ingredient: | Lenalidomide 15mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Te Arai BioFarma Limited |
Manufacturer: | Lotus Pharmaceutical Co Limited, Nantou City, Taiwan |
Note: This consent is given subject to the following conditions:
|
|
Note: This renewed consent is valid for two years from 24 October 2023. | |
Product: | Lenalidomide Te Arai |
Active Ingredient: | Lenalidomide 25mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Te Arai BioFarma Limited |
Manufacturer: | Lotus Pharmaceutical Co Limited, Nantou City, Taiwan |
Note: This consent is given subject to the following conditions:
|
|
Note: This renewed consent is valid for two years from 24 October 2023. |
Dated this 18th day of September 2023.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).